RSV-F protein subunit vaccine - GlaxoSmithKline

Drug Profile

RSV-F protein subunit vaccine - GlaxoSmithKline

Alternative Names: RSV F subunit vaccine; RSV fusion glycoprotein subunit vaccine; RSV-F protein vaccine

Latest Information Update: 05 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis Vaccines
  • Developer GlaxoSmithKline
  • Class Protein-vaccines; Proteins; Respiratory syncytial virus vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 27 Mar 2017 GlaxoSmithKline completes a phase I trial in Respiratory syncytial virus infection (In volunteers) in Belgium (NCT02298179)
  • 01 Dec 2014 Phase-I clinical trials in Respiratory syncytial virus infections (In adults, In volunteers) in Belgium (IM) (NCT02298179)
  • 25 Nov 2014 Novartis plans a phase I trial for Respiratory syncytial virus infections (In volunteers) in Belgium (NCT02298179)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top